

PROGRAM MATERIALS REQUIREMENTS

Cole Eye Institute Retina Summit
May 3, 2026 | Denver, CO



This activity is jointly provided by Global Education Group (Global) and iVista Medical Education, Inc.
This activity is supported by an educational grant from Apellis, Astellas, Genentech, Ocular Therapeutix and Regeneron.

Target Audience

The Cole Eye Institute Retina Summit is for retina specialists, comprehensive ophthalmologists, retina fellows, and healthcare providers who are interested in applying the most recent advancements in the retina.

Statement of Need/Program Overview

The annual Cole Eye Institute Retina Summit takes place live prior the ARVO Annual Meeting on Sunday, May 3, 2026 in Denver, Colorado. The summit will include didactic presentations and discussions focused on recent clinical study results and their application to clinical practice. The program will have interactive case-based sessions, with a dedicated audience question-and-answer session.

Educational Objectives

After completing this activity, the participant should be better able to:

- Evaluate strategies to improve disease monitoring and personalized treatment intervals in patients with neovascular AMD, including high-dose anti-VEGF therapy and home-based OCT.
- Describe the evolving treatment landscape in geographic atrophy (GA), including the clinical rationale for early intervention with complement inhibitors.
- Discuss emerging gene and cell-based therapies for retinal diseases including their mechanisms of action, including vector delivery strategies.
- Assess the clinical utility of multimodal imaging and artificial intelligence (AI) to enhance diagnosis, disease progression tracking, and treatment decision-making in retinal diseases.

Program Agenda

May 3, 2026 | 5:30 – 10:00 PM

5:30 PM – Registration, Exhibits and Welcome Reception

Physician Accreditation Statement



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and iVista Medical Education. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this live for a maximum of 2.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit, participants must complete the post test and evaluation. Participants must also score at least a 75 % on the post-test. To claim credit, complete the post-test and evaluation by following the link below:

<https://ivistameetings.com/meeting/cole-eye-institute-retina-summit-2026/>

Fee Information& Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Relevant Financial Relationships

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant

and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The **faculty** have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Justis Ehlers	Consulting Fee (e.g., Advisory Board): Zeiss, Leica/Bioptigen, Alcon, Beyeonics. Allergan, Allegro, Adverum, Regeneron, Roche, Genentech, RegenxBIO, Iveric Bio, Boehringer Ingelheim, Apellis, Novartis, Boehringer Ingelheim, Stealth BioTherapeutics, Perceive Biotherapeutics, Exegenesis, Ophthalmics, Eyepoint, Abbvie, Bayer, BVI, Alexion, Osanni, Johnson & Johnson, Ocular Therapeutix, OD-OS, Eyconis, Aviceda, Arrowhead, Character Bioscience, Alkeus Contracted Research (Principal Investigators must provide information, even if received by the institution): Regeneron, Genentech, Oxurion/Thrombogenics, Alcon, Aerpio, Allergan, Roche, Iveric Bio, Boehringer Ingelheim, Adverum, Novartis, Zeiss, Stealth BioTherapeutics, Perceive Biotherapeutics, Alexion, Beyeonics, Ocular Therapeutix.
Avni Finn	Consulting Fee (e.g., Advisory Board): Abbvie, Apellis, Genentech, Eyepoint, Bausch and Lomb Contracted Research (Principal Investigators must provide information, even if received by the institution): Regenexbio, ONL
Dilraj Grewal	Consulting Fee (e.g., Advisory Board): Apellis, Astellas, Zeiss, DORC, Regeneron, Genentech, ANI Pharmaceuticals, EyePoint Contracted Research (Principal Investigators must provide information, even if received by the institution): Priovant, Genentech, REGNxBio, Regeneron, Alumis
Hong-Uyen Hua	Consulting Fee (e.g., Advisory Board): Apellis, Alcon, Abbvie, Alimera, EyePoint Honoraria: Amgen
Hadi Kaakour	Nothing to disclose
Phoebe Lin	Consulting Fee (e.g., Advisory Board): Regeneron, Alimera Sciences
Thomas Mendel	Consulting Fee (e.g., Advisory Board): Insmad, Harrow Contracted Research (Principal Investigators must provide information, even if received by the institution): Alkeus
Prithvi Mruthyunjaya	Consulting Fee (e.g., Advisory Board): Alcon, Castle Biosciences, Genentech
Aleksandra Rachitskaya	Consulting Fee (e.g., Advisory Board): AbbVie/Allergan, Alcon, Apellis, Regeneron, Iveric Bio, Roche/Genentech, Ocular Therapeutix, Samsara Contracted Research (Principal Investigators must provide information, even if received by the institution): Beacon Therapeutics, Apellis Pharmaceuticals, DRCR Retina Network, and Roche/Genentech Speakers' Bureau: Apellis, Iveric Bio, Genentech, Regeneron
Prethy Rao	Consulting Fee (e.g., Advisory Board): Genentech, EyePoint, Bausch and Lomb Contracted Research (Principal Investigators must provide information, even if received by the institution): Abbvie, EyePoint, Genentech, Janssen Royalty: Vortex Surgical
Sumit Sharma	Consulting Fee (e.g., Advisory Board): 4DMT, Alimera, Abbvie, Apellis, Bausch and Lomb, Clearside, Eyepoint, Genentech/Roche, Iveric Bio, Kodiak, Regeneron, RegenXBio, Ripple, Volk, Zeiss Contracted Research (Principal Investigators must provide information, even if received by the institution): Acelyrin, Gilead, Genentech/Roche, Santen, IONIS, Kodiak
Sunil Srivastava	Consulting Fee (e.g., Advisory Board): Bausch and Lomb, Clearside, Zeiss, jCyte, Novartis, Regeneron, Gilead, Eyepoint Contracted Research (Principal Investigators must provide information, even if received by the institution): Gilead, Eyepoint, Regeneron
Rishi Singh	Consulting Fee (e.g., Advisory Board): Alcon, Bausch and Lomb, Adverum, Astellas, Eyepoint, Genentech, Regeneron, Apellis, Astellas, Topcon, Olin Bioscience, Aviceda, Outlook, Sanro
Katherine Talcott	Consulting Fee (e.g., Advisory Board): Alimera, Allergan, Apellis, Bausch and Lomb, Eyepoint, Genentech, Outlook, Regeneron, Zeiss Speakers' Bureau: Genentech, Iveric Bio, Zeiss
Alex Yuan	Nothing to disclose

The **planners and managers** with Global Education Group and iVista have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and iVista Medical Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.